Cerebrolysin for acute ischaemic stroke

Ziganshina, Liliya Eugenevna; Abakumova, Tatyana; Nurkhametova, Dilyara; Ivanchenko, Kristina

doi:10.1002/14651858.cd007026.pub7

Cited by 5 publications

(3 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This topic of neurocognitive changes in neurological patients who received these drugs/supplements also chosen for our patients is a topic that has captivated the interest of many researchers. Some studies proved the beneficial effect of Vitamin B1 on cognitive recovery in elders [63,64] and the impact of Cerebrolysin in the recovery of patients after neurological damage [35][36][37]46]. According to a couple of studies from the current literature, nutritional techniques or supplements may improve cognitive function, despite many unknown biochemical mechanisms [65][66][67].…”

Section: Discussionmentioning

confidence: 99%

“…Cerebrolysin is a medication that, for some time now, has been used in hospital settings to treat neurological problems such as strokes [32] and traumatic brain injuries [33], and it has captured the interest of the medical world for its beneficial effects [34]. It is a composed of low-molecular-weight peptides and amino acids [35], extracted from the braincells of a porcine [36]. There are some studies on animal models and observational studies on humans suggesting a beneficial effect of Cerebrolysin usage on cognition enhancement in patients with moderate to severe brain injuries [37].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Cognitive Function in Romanian Patients with Chronic Alcohol Consumption

Morega,

Ionele,

Podeanu

et al. 2024

Gastroenterology Insights

View full text Add to dashboard Cite

Alcoholism presents a significant health concern with notable socioeconomic implications. Alcohol withdrawal syndrome (AWS) can manifest when individuals cease or drastically reduce their alcohol consumption after prolonged use. Non-alcoholic fatty liver disease (NAFLD) is characterized by substantial lipid accumulation in the liver cells of individuals with no history of alcohol consumption. There is evidence suggesting an association between cognitive impairment and both conditions. This study aimed to evaluate cognitive impairment in patients with NAFLD and AWS using the Mini-Mental State Examination (MMSE). This study involved 120 patients admitted to two hospitals in Craiova, Romania. Results indicated that patients with NAFLD did not exhibit cognitive impairment as measured by MMSE (Mean = 29.27, SD = 0.785). Conversely, patients with AWS showed more pronounced cognitive dysfunction, with a mean MMSE score at admission of 16.60 ± 4.097 and 24.60 ± 2.832 after 2 weeks under treatment with Vitamins B1 and B6 and Cerebrolysin. Additionally, our findings suggested that cognitive dysfunction among alcohol consumers was correlated with the severity of clinical symptoms, as demonstrated by the severity of tremors in our study. The two-week period under treatment and alcohol withdrawal was insufficient for cognitive function to return to normal levels. Observational studies on longer periods of time are advised.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assessment of Cognitive Function in Romanian Patients with Chronic Alcohol Consumption

Morega,

Ionele,

Podeanu

et al. 2024

Gastroenterology Insights

View full text Add to dashboard Cite

show abstract

“…The most common adverse events were dizziness, headache, skin flushing, nausea, and systemic symptoms such as fatigue and insomnia. A recent update of the Cochrane review on cerebrolysin in acute ichaemic stroke-indicated moderate certainty of evidence for an increase in nonfatal serious adverse events with cerebrolysin use, in particular for a dose of 30 ml/day [ 19 ]. Interestingly, the study by Strilciuc et al indicated that compared to the placebo, the highest dose of cerebrolysin (50 mL, as we use it in sTBI) had the lowest occurrence rate of SAE and nonfatal SAE, with a risk reduction of >25%, thus suggesting some effects of the agent against adverse events [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Life‐Threatening Anaphylaxis due to Cerebrolysin®

Trimmel,

Tauber,

Zikeli

2024

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

In this case report, we describe a well‐documented, severe anaphylactic reaction after intravenous administration of cerebrolysin, a neurotrophic agent derived from highly purified porcine brain tissue, consisting of peptides and free amino acids. Cerebrolysin has been in use for decades, in various neurological diseases, but especially stroke and traumatic brain injury, with the aim of enhancing cognitive performance. After administration of cerebrolysin to an 85‐year‐old male patient suffering from subacute stroke, he developed a fulminant anaphylactic reaction. Following institutional standards, vital functions were quickly restored. The anaphylactic reaction was clearly confirmed by laboratory tests. To date, only rare cases of anaphylaxis due to cerebrolysin have been published in the literature. The current report is intended to raise awareness for the possibility of such a reaction, given the widespread use of cerebrolysin in several indications in mostly critical patients. The case shows how a completely unexpected life‐threatening situation can be successfully treated by targeted measures, if the situation is recognized quickly. In light of this event, we consider pathophysiology of allergic reactions and treatment guidelines.

show abstract